Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-25-180411
Filing Date
2025-08-14
Accepted
2025-08-14 08:39:09
Documents
23

Document Format Files

Seq Description Document Type Size
1 S-3 d121007ds3.htm S-3 460103
2 EX-1.2 d121007dex12.htm EX-1.2 196875
3 EX-4.11 d121007dex411.htm EX-4.11 286088
4 EX-4.12 d121007dex412.htm EX-4.12 283625
5 EX-5.1 d121007dex51.htm EX-5.1 15090
6 EX-5.2 d121007dex52.htm EX-5.2 8642
7 EX-23.1 d121007dex231.htm EX-23.1 3192
8 EX-FILING FEES d121007dexfilingfees.htm   iXBRL EX-FILING FEES 33644
9 GRAPHIC g121007g04v04.jpg GRAPHIC 44955
10 GRAPHIC g121007g0813152642093.jpg GRAPHIC 1784
11 GRAPHIC g121007g0813152642804.jpg GRAPHIC 2247
12 GRAPHIC g121007g90e73.jpg GRAPHIC 12815
  Complete submission text file 0001193125-25-180411.txt   1537883

Data Files

Seq Description Document Type Size
25 EXTRACTED XBRL INSTANCE DOCUMENT d121007dexfilingfees_htm.xml XML 15222
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-289595 | Film No.: 251214604
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)